Register
Login:
Share:
Email Facebook Twitter

Ian Williams, from Charteris Treasury, talks about investments in gold and silver Watch here

Ian Williams, from Charteris Treasury, talks about investments in gold and silver


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 205.00Bid: 200.00Ask: 210.00Change: 2.50 (+1.23%)Riser - Summit Ther
Spread: 10.00Spread as %: 5.00%Open: 207.50High: 207.50Low: 197.50Yesterday’s Close: 202.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
205.00

Share Price SpacerBid
200.00

Share Price SpacerAsk
210.00

Share Price SpacerChange
1.23%2.50

Share Price SpacerVolume
27,633

Share Price SpacerOpen
207.50

Share Price SpacerHigh
207.50

Share Price SpacerLow
197.50

Share Price SpacerClose
202.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.84m £126.78m 1,500

52 Week High 260.00 52 Week High Date 4-OCT-2016
52 Week Low 90.00 52 Week Low Date 16-SEP-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
13 20,133 7,500 -5.857 -35.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Mar-17
16:22:43
205.00
10,000
 
200.00
210.00
20.50k
Trade Type:
Ordinary

30-Mar-17
16:07:18
204.50
2,928
Sell* 
200.00
210.00
5,988
Trade Type:
Ordinary

30-Mar-17
15:56:17
202.00
1,900
Sell* 
200.00
205.00
3,838
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Today 17:36Free-MoneyRE: Delay/PRV205.00No Opinion
Delay, I'm looking at it favourably after listening to the call and Q&A's and regarding it more of a mitigating risk issue. They would only have F3 data from 6-8 boys ready for this Summer if they took that approach and that data may not show significance and, therefore, knock confidence in the programme. It is better to wait for the full 20 boys on the 24 week biopsy route and that would include F6 cases too.

PRV, as I understand it if the programme is still running would be awarded… Read More
Today 16:28egomonkeyDelay/PRV205.00No Opinion
This delay in reporting is concerning, especially as it's unexplained. I'd like to hear from Glen on this

On an unrelated note, does anyone know where we stand with the Priority Review Voucher? I know the programme was extended, but are we still eligible?

Sarepta sold theirs for $125M in Feb, so they still have pretty significant value
Today 10:03eurotoSummit and Sarepta200.00No Opinion
This kind of class action might apply to organisations such as AVO in my opinion too.
Today 08:36WalkleySummit and Sarepta207.50Strong Buy
Sarepta (market cap $1,580m) is in trouble over claims for its DMD candidate Eteplirsen - Scott + Scott lawyers trying to start a shareholder class action http://tinyurl.com/mykqdtx . Perhaps holders will switch to Summit (market cap $160m)
Wed 23:23Free-MoneyRE: RNS202.50No Opinion
DMD - high risk, high return
C.Diff - low risk modest return.

Since both still very much in play I see SUMM underpinned by the C.Diff programme but also with a good shot at the high return DMD programme..... in time.

Everyone should weigh the risks and their investment profile. GLA
Wed 18:31gmccRE: RNS202.50No Opinion
Hi everyone ! Here’s hoping that the DMD delay is purely clinical administration issues in getting DMD boys ready for treatment , rather than lack of F3 evidence treatment benefit .

Seems to be extra info due to be reported though !

Note SUMM are now saying 20 patients “We now look forward to providing the full analysis of 24-week biopsies from the approximately 20 patients dosed with the F3 or F6 formulation of ezutromid, plus 24-week MRI and functional… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.